txmd-8k_080613.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 


FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): August 6, 2013
 
TherapeuticsMD, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Nevada
 
000-16731
 
87-0233535
(State or Other
Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
6800 Broken Sound Parkway NW,
Third Floor
Boca Raton, FL 33487
(Address of Principal Executive Office) (Zip Code)
 
Registrant's telephone number, including area code:  (561) 961-1900
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
Item 2.02.
Results of Operations and Financial Condition.
 
On August 6, 2013, TherapeuticsMD, Inc. issued a press release announcing its results of operations for its second fiscal quarter ended June 30, 2013. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
 
The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
 
Item 9.01.
Financial Statements and Exhibits.

(d)           Exhibits.                       
 
   
Exhibit
Number
 
Description
   
99.1
 
Press Release from TherapeuticsMD, Inc., dated August 6, 2013, entitled “TherapeuticsMD Reports Second Quarter 2013 Financial Results”.
 
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date:  August 6, 2013   THERAPEUTICSMD, INC.
       
       
    By:  /s/ Daniel A. Cartwright
    Name: Daniel A. Cartwright
    Title: Chief Financial Officer
 
 
 
 

 
                                                                
 
    EXHIBIT INDEX
   
Exhibit
Number
 
Description
   
99.1